Integrated cancer networks improve compliance with national guidelines and outcomes for resectable gastric cancer
暂无分享,去创建一个
[1] Kitty S. Chan,et al. Evaluating Dissemination of Adequate Lymphadenectomy for Gastric Cancer in the USA , 2019, Journal of Gastrointestinal Surgery.
[2] J. Boughey,et al. ASO Author Reflections: A Statistical Caution Regarding Missing Clinical Stage in the National Cancer Database , 2019, Annals of Surgical Oncology.
[3] W. Cheng,et al. A Comprehensive Assessment of the Racial and Ethnic Disparities in the Incidence of Gastric Cancer in the United States, 1992-2014 , 2018, Cancer research and treatment : official journal of Korean Cancer Association.
[4] M. Shabahang,et al. Analyzing the Impact of Compliance with National Guidelines for Pancreatic Cancer Care Using the National Cancer Database , 2018, Journal of Gastrointestinal Surgery.
[5] S. Hochwald,et al. Disparities in major surgery for esophagogastric cancer among hospitals by case volume. , 2018, Journal of gastrointestinal oncology.
[6] Xianglin L. Du,et al. Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006‐2014 , 2018, Cancer.
[7] G. Salti,et al. Extensive Lymph Node Dissection Improves Survival among American Patients with Gastric Adenocarcinoma Treated Surgically: Analysis of the National Cancer Database , 2017, Journal of gastric cancer.
[8] C. Hollenbeak,et al. Timing of Adjuvant Chemotherapy and Impact on Survival for Resected Gastric Cancer , 2016, Annals of Surgical Oncology.
[9] J. Ajani,et al. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer , 2016, Annals of Surgical Oncology.
[10] D. Fraker,et al. Multimodality Therapy Improves Survival in Resected Early Stage Gastric Cancer in the United States , 2016, Annals of Surgical Oncology.
[11] D. Fraker,et al. Multimodality Treatment of T4 Gastric Cancer in the United States: Utilization Trends and Impact on Survival , 2015, Annals of Surgical Oncology.
[12] K. Hunt,et al. Operative standards for cancer surgery , 2015 .
[13] J. Norton,et al. Compliance with gastric cancer guidelines is associated with improved outcomes. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[14] D. Fraker,et al. Implications of inadequate lymph node staging in resectable gastric cancer: A contemporary analysis using the National Cancer Data Base , 2014, Cancer.
[15] D. Penson,et al. Trends in the use of evidence‐based therapy for resectable gastric cancer , 2014, Journal of surgical oncology.
[16] I. Choi,et al. Prognostic Impact of Microscopic Tumor Involved Resection Margin in Advanced Gastric Cancer Patients after Gastric Resection , 2014, World Journal of Surgery.
[17] Percy Lee,et al. Benefit of Adjuvant Chemoradiotherapy for Gastric Adenocarcinoma: A SEER Population Analysis. , 2013, Gastrointestinal cancer research : GCR.
[18] A. Benson,et al. Treatment Trends and Predictors of Adjuvant and Neoadjuvant Therapy for Gastric Adenocarcinoma in the United States , 2013, Annals of Surgical Oncology.
[19] B. Feig,et al. Do Hospital Attributes Predict Guideline-Recommended Gastric Cancer Care in the United States? , 2012, Annals of Surgical Oncology.
[20] A. Stewart,et al. Variations in gastric cancer care , 2010, Cancer.
[21] C. Ko,et al. Using the NCDB for cancer care improvement: An introduction to available quality assessment tools , 2009, Journal of surgical oncology.
[22] C. Ko,et al. Effect of hospital type and volume on lymph node evaluation for gastric and pancreatic cancer. , 2008, Archives of surgery.
[23] J. Ajani,et al. Treatment of Gastric Adenocarcinoma May Differ Among Hospital Types in the United States, a Report from the National Cancer Data Base , 2007, Journal of Gastrointestinal Surgery.
[24] D. Gouma,et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] D. Gouma,et al. Extended lymph-node dissection for gastric cancer. , 1999, The New England journal of medicine.
[26] P. Fayers,et al. Patient survival after D 1 and D 2 resections for gastric cancer: long-term results of the MRC randomized surgical trial , 1999, British Journal of Cancer.
[27] P. Fayers,et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial , 1996, The Lancet.
[28] J. Hermans,et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients , 1995, The Lancet.
[29] M. Senthil,et al. The role of the cancer center when using lymph node count as a quality measure for gastric cancer surgery. , 2015, JAMA surgery.
[30] L. Tanoue,et al. The National Comprehensive Cancer Network , 1998, Cancer.
[31] H. Putter,et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. , 2010, The Lancet. Oncology.
[32] E. Jensen,et al. Guideline Recommended Gastric Cancer Care in the Elderly: Insights into the Applicability of Cancer Trials to Real World , 2010, Annals of Surgical Oncology.
[33] J. Meyerhardt,et al. Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M. Huguier,et al. [Extended lymph-node dissection for gastric cancer]. , 1999, Chirurgie; memoires de l'Academie de chirurgie.
[35] G. Fleuren,et al. Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. , 1995, Journal of Clinical Oncology.